Earnings8-K
Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
SPRY
Ars Pharmaceuticals, Inc.
A maker of neffy, the first FDA-approved needle-free nasal spray for emergency treatment of severe allergic reactions (anaphylaxis), replacing the familiar auto-injector shot. Founded in 2015 by Richard Lowenthal, Dr. Sarina Tanimoto, and Dr. Robert Bell, the company's name is understood to reflect its focus on the allergic reaction system. neffy marked the first significant innovation in epinephrine delivery in over 35 years, offering a needle-free option for people who fear or avoid injectors.
CUSIP: 82835W108HealthcareUS1 holder